Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 02, 2002
IMPAX ANDA Filing for Generic Version of Tricor Tablets Accepted by FDA
Nov 26, 2002
IMPAX Provides Update on Strategic Alliance with Teva
Nov 11, 2002
IMPAX Receives FDA Approval for Omeprazole, a Generic Version of Prilosec
Nov 04, 2002
IMPAX to Present at CIBC World Markets 13th Annual Healthcare Conference
Oct 28, 2002
IMPAX Reports Record Sales in Third Quarter
Oct 22, 2002
IMPAX Laboratories to Hold Third Quarter Financial Results Conference Call Monday, October 28
Sep 26, 2002
IMPAX Comments on Purdue Pharma Lawsuit Related to Its Generic Version of OxyContin
Sep 03, 2002
IMPAX Receives FDA Approval for Generic Flumadine
Aug 26, 2002
IMPAX Receives Summary Judgment of Non-Infringement for Wellbutrin SR and Zyban ANDAs
Aug 22, 2002
IMPAX ANDA Filing for Generic Version of Oxycontin 40MG Accepted By FDA
Jul 25, 2002
IMPAX Reports Second Quarter Financial Results
Jul 22, 2002
IMPAX Receives Tentative FDA Approval for Generic Rilutek
Jun 24, 2002
IMPAX Announces Agreement with Schering-Plough to Supply CLARITIN-D 12 Hour for OTC Market
Jun 20, 2002
IMPAX Announces OTC Alliance with Wyeth
Jun 19, 2002
IMPAX To Present At Wachovia Securities 2002 Nantucket Equity Conference
Jun 18, 2002
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical
Jun 03, 2002
IMPAX Strengthens Brand Development Team
May 31, 2002
IMPAX to Present at UBS Warburg Global Specialty Pharmaceuticals Conference
May 30, 2002
IMPAX Receives FDA Tentative Approval for a Generic Version of Claritin-D 12-Hour
May 29, 2002
IMPAX Receives FDA Tentative Approval for a Generic Version of Claritin-D 24-Hour
May 23, 2002
IMPAX Shareholders Re-Elect Board Members
Apr 30, 2002
IMPAX Reports First Quarter Financial Results
Apr 29, 2002
IMPAX To Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Apr 26, 2002
IMPAX Comments on Purdue Pharma Lawsuit Related to Its Generic Version of Oxycontin
Apr 01, 2002
IMPAX to Present at Banc of America Securities Healthcare Conference 2002
Apr 01, 2002
IMPAX Comments On Aventis Pharmaceuticals Lawsuit Related to Generic Version of Allegra-D
Mar 19, 2002
IMPAX Receives FDA Approval To Market Fludrocortisone Acetate Tablets
Mar 18, 2002
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical
Mar 13, 2002
IMPAX Comments on Claritin Announcement by Schering-Plough
Feb 26, 2002
IMPAX ANDA Filing for Generic Version of Oxycontin Accepted by FDA
Feb 25, 2002
IMPAX to Present at Lehman Brothers 5th Annual Global Healthcare Conference
Feb 21, 2002
IMPAX Receives FDA Tentative Approval of Fenofibrate ANDA
Feb 12, 2002
IMPAX ANDA Filing for Generic Version of Allegra-D Accepted By FDA
Feb 07, 2002
Impax Laboratories Reports Fourth Quarter and Record Full Year 2010 Financial Results

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top